Advertisement

Topics

Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin

2014-08-27 03:18:58 | BioPortfolio

Summary

Ascites is a common complication of cirrhosis. Sodium restriction and diuretics are the first step treatment. Refractory ascites (not responding to first step treatment) is treated with repeated large volume paracentesis followed by intra venous albumin expansion. In pilot studies vasoconstrictor agents such as terlipressin have shown beneficial effect on ascites production. Therefore the investigators will study the effect of combined therapy with albumin and terlipressin on recidivation ascites.

Description

About 30% of cirrhotic patients will develop ascites. Sodium restriction and diuretics are the first step treatment. Total paracentesis is used in patients with cirrhosis and tense ascites. Paracentesis alone was found to induce a decrease in effective arterial blood volume. This circulatory dysfunction may induce inhospital complications such as impaired renal function or hyponatremia and is associated with a significant reduction in long term survival. Intravenous albumin administration after paracentesis has been shown to prevent the post paracentesis decrease in arterial blood volume. Paracentesis also induces arteriolar vasodilation which plays a major role in initiating the decrease in arterial blood volume. Therefore, administration of a vasoconstrictor may decrease paracentesis induced arteriolar vasodilation and prevent the resulting decrease in effective arterial blood volume. Two randomised pilot studies suggest that Terlipressin may be as effective as intravenous albumin in preventing a decrease in effective arterial blood volume in patients with cirrhosis treated by paracentesis for tense ascites. The combined treatment, albumin plus terlipressin, could have additional effect and may improve ascites in such patients. In several studies the combined therapy, albumin plus terlipressin, has shown beneficial effect in cirrhotic patients with hepatorenal syndrome characterized by a sever decrease in arterial blood volume and vasodilation. In these studies, combined therapy was well tolerated.The aim of this study is to compare ascites relapse between two groups of cirrhotic patients with recidivation ascites treated by paracentesis and intravenous albumin perfusion plus terlipressin or placebo. In this double blind randomized multi-center trial, all patients receive albumin perfusion at the dose 8 g/l of removed ascites and Terlipressin (1mg) or placebo, administrated before and at the end of the paracentesis.

Study Design

Allocation: Randomized, Control: Placebo Control, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Cirrhosis

Intervention

Terlipressin, Placebo

Location

CARBONELL Nicolas
Paris
France
75012

Status

Recruiting

Source

Assistance Publique - Hôpitaux de Paris

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:18:58-0400

Clinical Trials [388 Associated Clinical Trials listed on BioPortfolio]

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis

Terlipressin is the mainstay drug for the treatment of acute variceal bleeding in liver cirrhosis. According to the drug instructions, intravenous bolus infusion is the standard approach o...

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

From 1999, several studies have showed that the use of vasoconstrictors in association with albumin are effective in the treatment of hepatorenal syndrome (HRS). The rationale of the use o...

Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin

Hepatorenal syndrome is a common complication of cirrhotic patients. The prognosis of patients with HRS is very poor. It have been demonstrated that vasoconstrictors agents (Terlipressin) ...

Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites

The purpose of this study is to investigate the effect of terlipressin on myocardial perfusion and renal function. Hypothesis: Significant improvement of renal function reflected by: glom...

Terlipressin in Septic Shock in Cirrhosis

Septic shock is a frequent and severe complication in cirrhosis. Current mortality rate ranges between 50 and 80% of cases. Refractory shock, hepatorenal failure and variceal bleeding are ...

PubMed Articles [1336 Associated PubMed Articles listed on BioPortfolio]

Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure.

Hepatorenal syndrome (HRS) carries a high short-term mortality in patients with cirrhosis and ACLF. Terlipressin and noradrenaline are routinely used in cirrhosis with HRS and have been found to be eq...

"Letter To Editor: Terlipressin is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute On Chronic Liver Failure".

The article by Arora et al. (2018) compared use of two vasoconstrictors terlipressin and noradrenaline in the management of acute kidney injury in ACLF patient. Numerous other trials have shown no di...

Severe reversible penile ischaemia after terlipressin treatment of hepatorenal syndrome.

This case report presents a 70-year-old man with alcoholic liver cirrhosis, who was hospitalised due to pulmonary oedema, and who developed acute renal injury. Though the criteria were not fulfilled, ...

Letter to editor: Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute-on-chronic liver failure.

We read with interest the paper by Arora et al comparing terlipressin with noradrenaline in the management of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF). The aut...

The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options.

Although patients with cryptogenic cirrhosis have been historically considered to have "burnt out" nonalcoholic steatohepatitis (NASH), some controversy remains. The aim was to compare outcomes of pat...

Medical and Biotech [MESH] Definitions

Experimentally induced chronic injuries to the parenchymal cells in the liver to achieve a model for LIVER CIRRHOSIS.

FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.

More From BioPortfolio on "Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Searches Linking to this Trial